Literature DB >> 23183921

Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease.

David A Ziegler1, Julien S Wonderlick, Paymon Ashourian, Leslie A Hansen, Jeremy C Young, Alex J Murphy, Cecily K Koppuzha, John H Growdon, Suzanne Corkin.   

Abstract

OBJECTIVE: To test the hypothesis that degeneration of the substantia nigra pars compacta (SNc) precedes that of the cholinergic basal forebrain (BF) in Parkinson disease (PD) using new multispectral structural magnetic resonance (MR) imaging tools to measure the volumes of the SNc and BF.
DESIGN: Matched case-control study.
SETTING: The Athinoula A. Martinos Imaging Center at the McGovern Institute for Brain Research, Massachusetts Institute of Technology (MIT), and the Massachusetts General Hospital/MIT Morris Udall Center of Excellence in Parkinson Disease Research. PATIENTS: Participants included 29 patients with PD (Hoehn and Yahr [H&Y] stages 1-3) and 27 matched healthy control subjects. MAIN OUTCOME MEASURES: We acquired multiecho T1-weighted, multiecho proton density, T2-weighted, and T2-weighted fluid-attenuated inversion recovery (FLAIR) sequences from each participant. For the SNc, we created a weighted mean of the multiple echoes, yielding a single volume with a high ratio of contrast to noise. We visualized the BF using T2-weighted FLAIR images. For each participant, we manually labeled the 2 structures and calculated their volumes.
RESULTS: Relative to the controls, 13 patients with H&Y stage 1 PD had significantly decreased SNc volumes. Sixteen patients with H&Y stage 2 or 3 PD showed little additional volume loss. In contrast, the BF volume loss occurred later in the disease, with a significant decrease apparent in patients having H&Y stage 2 or 3 PD compared with the controls and the patients having H&Y stage 1 PD. The latter group did not differ significantly from the controls.
CONCLUSION: Our results support the proposed neuropathological trajectory in PD and establish novel multispectral methods as MR imaging biomarkers for tracking the degeneration of the SNc and BF.

Entities:  

Mesh:

Year:  2013        PMID: 23183921      PMCID: PMC5751707          DOI: 10.1001/jamaneurol.2013.597

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  45 in total

1.  Critical evaluation of the Braak staging scheme for Parkinson's disease.

Authors:  Kurt A Jellinger
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

Review 2.  Parkinson's disease: genetics and pathogenesis.

Authors:  Joshua M Shulman; Philip L De Jager; Mel B Feany
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

3.  Mild cognitive impairment in the elderly is associated with volume loss of the cholinergic basal forebrain region.

Authors:  Kathrin Muth; Ralf Schönmeyer; Silke Matura; Corinna Haenschel; Johannes Schröder; Johannes Pantel
Journal:  Biol Psychiatry       Date:  2009-04-17       Impact factor: 13.382

4.  Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease.

Authors:  M Ruberg; F Rieger; A Villageois; A M Bonnet; Y Agid
Journal:  Brain Res       Date:  1986-01-01       Impact factor: 3.252

5.  Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease.

Authors:  I Nakano; A Hirano
Journal:  Ann Neurol       Date:  1984-05       Impact factor: 10.422

6.  Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts.

Authors:  S Y Ma; M Röyttä; J O Rinne; Y Collan; U K Rinne
Journal:  J Neurol Sci       Date:  1997-10-03       Impact factor: 3.181

7.  Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease.

Authors:  T Arendt; V Bigl; A Arendt; A Tennstedt
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

8.  Basal forebrain neurons in the dementia of Parkinson disease.

Authors:  P J Whitehouse; J C Hedreen; C L White; D L Price
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

Review 9.  Treatments for Parkinson disease--past achievements and current clinical needs.

Authors:  Werner Poewe
Journal:  Neurology       Date:  2009-02-17       Impact factor: 9.910

10.  The nucleus basalis of Meynert in neurological disease: a quantitative morphological study.

Authors:  J D Rogers; D Brogan; S S Mirra
Journal:  Ann Neurol       Date:  1985-02       Impact factor: 10.422

View more
  22 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  Technology: Multiple exposure.

Authors:  Neil Savage
Journal:  Nature       Date:  2013-10-31       Impact factor: 49.962

3.  Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat.

Authors:  Michelle Healy-Stoffel; S Omar Ahmad; John A Stanford; Beth Levant
Journal:  Brain Res       Date:  2014-06-09       Impact factor: 3.252

Review 4.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

Review 5.  Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

Authors:  Martin Sarter; Roger L Albin; Aaron Kucinski; Cindy Lustig
Journal:  Exp Neurol       Date:  2014-05-05       Impact factor: 5.330

6.  New MRI Biomarkers Advance the Characterization of Parkinson Disease.

Authors:  David A Ziegler; Suzanne Corkin
Journal:  Eur Neurol Rev       Date:  2013

Review 7.  The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes.

Authors:  Florian Holtbernd; David Eidelberg
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

Review 8.  Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline.

Authors:  Elizabeth C Ballinger; Mala Ananth; David A Talmage; Lorna W Role
Journal:  Neuron       Date:  2016-09-21       Impact factor: 17.173

9.  Harnessing advances in structural MRI to enhance research on Parkinson's disease.

Authors:  David A Ziegler; Jean C Augustinack
Journal:  Imaging Med       Date:  2013-04

10.  Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms.

Authors:  David A Ziegler; Paymon Ashourian; Julien S Wonderlick; Alison K Sarokhan; Drazen Prelec; Clemens R Scherzer; Suzanne Corkin
Journal:  Scand J Psychol       Date:  2014-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.